<nel class="sljna"></nel>

z6com时凯集团

Be the most trusted biotech company

2022-08-15

First Subject Dosed of the Phase 1 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Advanced/Metastatic Solid Tumours Patients
2022-07-29

Mars landing H - Boarding Call for Innovation
2022-07-25

Henlius HANQUYOU Received TGA Approval in Australia
2022-07-19

Henlius Denosumab Biosimilar HLX14 Received Clinical Trial Approval in Australia for the Phase 3 MRCT
2022-07-06

First Subject Dosed in China on Phase 1/2 Trial of Henlius' Anti-PD-L1×TIGIT Bispecific Antibody
2022-06-30

Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53 IND Approved by NMPA
2022-06-28

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
2022-06-23

Henlius’ Self-developed Asymmetric Multichain Bispecific Antibody Cell Line Leading the Industry with High Titer and Purity
2022-06-21

Henlius’ Songjiang First Plant Received QP Declaration of Its GMP Equivalence to EU GMP